Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler (Q47990285)

7 February 2018

title

Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler (English)

1 reference

7 February 2018

1 reference

1 reference

Rachel Yoon Kyung Chang

1 reference

7 February 2018

Hak-Kim Chan

1 reference

7 February 2018

Sharon S Y Leung

0 references

Graham F Hatfull

1 reference

7 February 2018

author name string

Nicholas B Carrigy

1 reference

7 February 2018

Melissa Harrison

1 reference

7 February 2018

Zaritza Petrova

1 reference

7 February 2018

Welkin H Pope

1 reference

7 February 2018

Warwick J Britton

1 reference

7 February 2018

Dominic Sauvageau

1 reference

7 February 2018

Warren H Finlay

1 reference

7 February 2018

Reinhard Vehring

1 reference

7 February 2018

publication date

23 June 2017

1 reference

7 February 2018

published in

Pharmaceutical Research

1 reference

7 February 2018

volume

1 reference

7 February 2018

issue

1 reference

7 February 2018

page(s)

2084-2096

1 reference

7 February 2018

Totally drug-resistant tuberculosis in India.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Phage treatment of human infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Bacteriophages as potential new therapeutics to replace or supplement antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Taking bacteriophage therapy seriously: a moral argument

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Pros and cons of phage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Respirable bacteriophages for the treatment of bacterial lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Phage Therapy in Clinical Practice: Treatment of Human Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Manufacturing and device options for the delivery of biotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Phage therapy of pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Inhalation Study of Mycobacteriophage D29 Aerosol for Mice by Endotracheal Route and Nose-Only Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

A review of the development of Respimat Soft Mist Inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Impact of relative humidity and collection media on mycobacteriophage D29 aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Studies on aerosol delivery of plasmid DNA using a mesh nebulizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Use of Extrathoracic Deposition Models for Patient-Specific Dose Estimation during Inhaler Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Acid resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Titer dynamic analysis of D29 within MTB-infected macrophages and effect on immune function of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Phage Inhibit Pathogen Dissemination by Targeting Bacterial Migrants in a Chronic Infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Dispersing biofilms with engineered enzymatic bacteriophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

D-amino acids trigger biofilm disassembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-017-2213-4

The antibiotic resistance crisis: part 1: causes and threats

21 January 2018

1 reference

12 December 2020

Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections

1 reference

12 December 2020

Bacteriophage active against virulent Mycobacterium tuberculosis. I. Isolation and activity

1 reference

12 December 2020

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders

1 reference

12 December 2020

The role of regulated clinical trials in the development of bacteriophage therapeutics

1 reference

12 December 2020

10.1007/S11095-017-2213-4

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018